ML277 , ≥98%(HPLC) , 1401242-74-7

Synonym(s):
(2R)-N-[4-(4-Methoxyphenyl)-1,3-thiazol-2-yl]-1-(4-methylphenyl)sulfonylpiperidine-2-carboxamide;(R)-N-(4-(4-Methoxyphenyl)thiazol-2-yl)-1-tosylpiperidine-2-carboxamide;CID-53347902;VU0458298-2, VU0458298-3

CAS NO.：1401242-74-7

Empirical Formula: C23H25N3O4S2

Molecular Weight: 471.59

MDL number: MFCD23704792

PRODUCT Properties

• Density: 1.341±0.06 g/cm3(Predicted)
• storage temp.: 2-8°C
• solubility: DMSO: 5 mg/ml
• pka: 8.37±0.70(Predicted)
• form: powder
• color: white to beige

Description and Uses

Potassium (K⁺) channels are categorized by their mode of activation and the number of transmembrane segments. The voltage-gated six-transmembrane K⁺ channels include KCNQ1, first recognized for its role in cardiac function and subsequently in hearing, gastrointestinal chloride secretion, and other processes. ML-277 is a potent activator of KCNQ1 channels (EC₅₀ = 260 nM). The EC₅₀ value of this compound at the related channels KCNQ2, KCNQ4, and hERG exceeds 30 μM. ML-277 potentiates both homomultimeric KCNQ1 channels and unsaturated heteromultimeric (KCNQ1/KCNE1) channels in model cardiomyocytes and augments delayed rectifier K⁺ current in cultured human cardiomyocytes.

ML277 has been used as the KCNQ1 activator to treat?cells in lung metastasis?assay.

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H302-H319
• Precautionary statements: P264-P270-P280-P301+P312-P305+P351+P338-P337+P313
• Hazard Codes: Xn
• Risk Statements: 22-36
• Safety Statements: 26
• WGK Germany: 3